Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board of directors (the "**Board**") of Suzhou Basecare Medical Corporation Limited (the "**Company**") is pleased to announce the audited consolidated results of the Company and its subsidiaries (together, the "**Group**") for the year ended December 31, 2020, together with comparative audited figures for the same period of 2019.

In this announcement, "we", "us", and "our" refer to the Company (as defined above) and where the context otherwise requires, the Group (as defined above).

FINANCIAL SUMMARY

	Year ended December 31,		
	2020	2019	2018
	RMB'000	*RMB'000*	*RMB'000*
Revenue	**81,109**	55,685	32,609
Cost of sales	**(53,395)**	(29,432)	(24,472)
Gross profit	**27,714**	26,253	8,137
Loss from operations	**(53,468)**	(8,730)	(51,816)
Loss before taxation	**(881,518)**	(530,570)	(157,005)
Loss for the year	**(877,959)**	(533,997)	(157,700)

	Year ended December 31,		
	2020	2019	2018
	RMB'000	*RMB'000*	*RMB'000*
Financial Position			
Non-current assets	**39,905**	36,187	39,984
Current assets	**310,393**	114,941	108,274
Non-current liabilities	**781**	1,044,863	505,857
Current liabilities	**68,182**	52,161	54,300
Net assets/(liabilities)	**281,335**	(945,896)	(411,899)
Total equity attributable to			
Equity shareholders of the Company	**281,335**	(938,853)	(407,517)
Non-controlling interests	**—**	(7,043)	(4,382)

MANAGEMENT DISCUSSION AND ANALYSIS

Overview

We are an innovative platform of genetic testing solutions for assisted reproduction in China. Our mission is to help more families have healthy babies. Our vision is becoming a global genetic technology company.

Our PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in *in vitro* fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA, compare to other PGT-A products based on fluorescence *in situ* hybridization (FISH) and quantitative polymerase chain reaction (qPCR) technologies. The NMPA registration of our PGT-A kit, in February 2020, as a Class III "innovative medical device," marked the birth of a regulated third-generation IVF market in China in which we are, to date, the only approved kit maker. There are other PGT-A kits in China that are applying for the NMPA registration certificate and sold for limited scientific research purposes.

We are developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR kits, which, together with our PGT-A kit, would form a complete test kit lineup to occupy the PGT field, all based on next-generation sequencing, or NGS, technologies. PGT-M looks for single-gene, or monogenic, defects in pre-implantation IVF embryos. We have developed a PGT-M kit with improved sensitivity and specificity. It eliminates the need for patient-specific pre-exam validation, offering a standardized solution with mass clinical appeal that significantly shortens results turnaround time from approximately two months to around two weeks, thereby reducing testing costs for patients as well. To date our PGT-M kit is the first and only product of its kind that has completed the registration testing in China. PGT-SR looks for chromosomal structural rearrangements, including deletions, duplications, inversions and translocations, in pre-implantation IVF embryos. There have been no effective clinical solutions for this test due to the many kinds of potential structural rearrangements occurring on different chromosomes, which requires clinicians to design non-standardized, bespoke tests, making mass clinical application difficult. Our PGT-SR kit may become the first standardized commercial product of its kind in China with potential for mass clinical application, at affordable prices. Our PGT-SR kit has high mass-market potential, offering one test with broad disease detectability and eliminating the need for patient-specific pre-exam validation, which translates to faster result turnaround time from three to six months to just two weeks and significantly lower costs for patients. We expect to obtain NMPA registration approval for PGT-M and PGT-SR kits in 2022 and 2024, respectively, which we anticipate would further our dominance in the third-generation IVF genetic test kit market in China, well ahead of potential competition.

Leveraging our core strength in PGT, we have positioned ourselves to become an innovative platform in China's broader reproductive genetics market. We have extended our reach beyond the pre-implantation stage to the prenatal and postnatal stages, and are developing one kit in each stage, which makes us a company in China with a genetic test kit pipeline that covers the full reproductive cycle, according to Frost & Sullivan. Beyond test kits, we have developed a number of innovative devices and instruments that can improve work flow in molecular genetic laboratories using our kits.

The following diagram sets forth key details of our product portfolio as of the date of this announcement:



* Includes principal raw material selection, manufacturing process validation and reaction system development

** Includes analytical performance evaluations and stability study

*** Refers to tests conducted by NMPA-recognised institutions to evaluate the performance of a medical device candidate. Passing the tests is a prerequisite to commencing the clinical trial

**** Unlike drugs, only one clinical trial is required for a medical device candidate, without phasing

1. For women undergoing IVF treatment who are 35 years old or older, couples who have experienced three or more IVF failures, couples who have experienced three or more spontaneous miscarriages or abnormal pregnancies, couples who have previously given birth to a child with chromosomal abnormalities or couples with chromosomal numerical alternations

2. For carriers of thalassemia

3. For carriers of chromosomal reciprocal translocation, Robertsonian translocation or inversion

4. For patients who have experienced miscarriage

5. For carriers of over 200 genetic diseases

Manufacturing

We manufacture and assemble all of our in-house developed products in our manufacturing facility in Suzhou. Our manufacturing facility is designed in compliance with the GMP requirements of China with an annual production capacity of 400,000 reactions. We are accredited in accordance with ISO13485:2016 quality standard, an international quality control standard for the medical device industry. We have two ISO Class 7 cleaning rooms that are in compliance with ISO14644–1 cleaning grades standard, an international cleaning grades classification standard. We have commenced optimizing our production process to prepare us for commercial-scale manufacturing of our PGT-A kits after we had obtained a Class III medical device registration certificate from the NMPA. Our production lines are designed to be highly automated.

Commercialization

We sold a significant portion of products directly to hospitals and reproductive clinics. To a lesser extent, we also sold our genetic test kits to distributors, who in turn sold our products to hospitals and reproductive clinics. We maintain a small and dedicated in-house sales and marketing team with a focus on serving key customers, such as third-generation IVF licensed hospitals and reproductive clinics, which are a major component of our customer base. Our in-house sales and marketing team is also responsible for the promotion of our products to hospitals and reproductive clinics through academic marketing activities, to interact with KOLs as well as other industry professionals.

With the first and only NMPA-approved PGT kit in China, we believe that we enjoy first-mover advantages in building and solidifying our sales channels and customer base. We plan to focus our commercialization strategy on key hospitals and reproductive clinics. We will leverage the relationships we have built with these hospitals and clinics for PGT-A to extend the breadth and depth of our coverage. We aim to increase our coverage and penetration of hospitals and reproductive clinics licensed to conduct PGT, and develop stronger relationships with them to enhance customer stickiness and lay the foundation to offer other products to them in the future. We plan to work toward full coverage of licensed hospitals and reproductive clinics in China. Moreover, we plan to expand our share of wallet in these hospitals and clinics by offering comprehensive solutions, with new products that target other medical specialties, such as the neonatal and pediatrics units, in these institutions. We also plan to partner with licensed third-party medical testing laboratories to extend our ability to reach a larger patient base in China.

Impact of the COVID-19 Outbreak

In December 2019, a respiratory illness known as COVID-19 caused by a novel strain of coronavirus emerged and has spread globally since then. We have employed various measures to mitigate any impact the COVID-19 outbreak may have on our operations in China or the development of our products, including offering personal protection equipment such as masks to our employees, regularly checking the body temperature of our employees and closely monitoring their health conditions.

As of the date of this announcement, the COVID-19 outbreak did not have a material and adverse impact on our business, financial condition and results of operations. Moreover, we currently do not expect the COVID-19 outbreak to have any material long-term impact on our operations or cause us to deviate from our overall development plans.

It is uncertain when and whether COVID-19 could be contained globally. We cannot guarantee you, however, that the COVID-19 outbreak will not further escalate or have a material adverse effect on our results of operations, financial position or prospects.

Important Events after the End of the Reporting Period

Since February 8, 2021 when the Company was successfully listed on the Main Board of the Stock Exchange, the Company has been making significant progress with respect to business operations, including the following milestones and achievements:

In February 2021, a self-developed patent relating to the PGT-SR kit, a nucleic acid library preparation method and its application in the analysis of pre-implantation embryonic chromosomal structure abnormalities (一種核酸文庫構建方法及其在植入前胚胎染色體結構異常分析中的應用), was registered with China National Intellectual Property Administration.

On March 4, 2021, the Company entered into a confirmation letter with the Suzhou Industrial Park Planning and Construction Committee, pursuant to which the Suzhou Industrial Park Planning and Construction Committee has confirmed, and the Company has acknowledged, that the Company has won the bid for the land use right of a piece of land of a total site area of 21,626.14 sq.m. for industrial purpose located to the east of Xingtang Street and north of Jiangyun Road, Suzhou Industrial Park, Jiangsu, PRC at a total consideration of RMB7,960,000.

On March 6, 2021, the Company entered into a research results transformation collaboration agreement (研究成果轉化合作協議, the "**Collaboration Agreement**") with Suzhou BioX Life Intelligence Industry Research Institute (蘇州超雲生命智能產業研究院有限公司) ("**Suzhou BioX**"). According to the Collaboration Agreement, Suzhou BioX agreed to provide academic research services in relation to the application of AI technologies in genetic disease diagnosis and genetic counseling and the Company agreed to leverage our extensive industry experience to provide services for developing products based on the academic research results and intellectual properties of Suzhou BioX.

On March 8, 2021, the Company successfully issued and allotted additional 6,859,000 H Shares of the Company pursuant to the over-allotment option, at the offer price of HK$27.36 per H Share.

For details of any of the foregoing, please refer to the Company's prior announcements published on the websites of the Stock Exchange and the Company.

Save as disclosed above, there are no important events occurred after the end of Reporting Period and up to the date of this annual results announcement.

FUTURE AND OUTLOOK

According to Frost & Sullivan, the total size of China's market of reproductive genetics medical devices increased from RMB1.3 billion in 2015 to RMB4.3 billion in 2020, and is expected to reach RMB11.2 billion in 2024. Our mission is to develop and launch innovative genetic testing solutions that are specifically designed for the Chinese population and that address unmet clinical needs in China. Our vision is to help more families have healthy babies. Our vision is becoming a global genetic technology company.

To accomplish that vision, we intend to implement the following business strategies: (i) continue to capture and solidify sales channels and customer base for PGT-A; (ii) rapidly commercialize product portfolio to occupy full reproductive cycle; (iii) develop next-generation automated and intelligent hardware to upgrade industry infrastructure; and (iv) maintain technological leadership by leveraging advancements of global leaders.

Cautionary Statement required under Rule 18A.08(3) of the Listing Rules: We cannot guarantee that we will ultimately develop or market our Core Product successfully.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	**2020** ***RMB'000***	2019 *RMB'000*
Continuing Operations			
Revenue	*3*	**81,109**	55,685
Cost of sales		**(53,395)**	(29,432)
Gross profit		**27,714**	26,253
Other income	*4*	**2,790**	3,958
Other losses		**(7,631)**	(55)
Distribution costs		**(16,616)**	(11,011)
Administrative expenses		**(25,244)**	(7,990)
Research and development expenses		**(34,481)**	(19,885)
Loss from operations		**(53,468)**	(8,730)
Finance costs	*5(a)*	**(1,472)**	(1,316)
Share of profit/(loss) of associates		**250**	(76)
Changes in the carrying amount of financial instruments issued to investors		**(826,828)**	(520,448)
Loss before taxation	*5*	**(881,518)**	(530,570)
Income tax	*6*	**7,394**	2,290
Loss for the year from continuing operations		**(874,124)**	(528,280)
Discontinued operations			
Loss for the year from discontinued operations		**(3,835)**	(5,717)
Loss for the year		**(877,959)**	(533,997)
Other comprehensive income		**—**	—
Total comprehensive income for the year		**(877,959)**	(533,997)

	Note	2020 *RMB'000*	2019 *RMB'000*
Loss for the year attributable to equity shareholders of the Company:			
— from continuing operations		**(874,124)**	(528,280)
— from discontinued operations		**(2,928)**	(3,056)
Loss for the year attributable to equity shareholders of the Company		**(877,052)**	(531,336)
Loss for the year attributable to non-controlling interests:			
— from continuing operations		**—**	—
— from discontinued operations		**(907)**	(2,661)
Loss for the year attributable to non-controlling interests		**(907)**	(2,661)
Loss for the year		**(877,959)**	(533,997)
Other comprehensive income		**—**	—
Total comprehensive income for the year		**(877,959)**	(533,997)
Total comprehensive income for the year attributable to:			
Equity shareholders of the Company		**(877,052)**	(531,336)
Non-controlling interests		**(907)**	(2,661)
Total comprehensive income for the year		**(877,959)**	(533,997)
Loss per share	*7*		
Basic and diluted (RMB)		**(5.1)**	(3.6)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Note	**December 31 2020** ***RMB'000***	December 31 2019 *RMB'000*
Non-current assets			
Property, plant and equipment		**18,618**	21,775
Right-of-use assets		**1,440**	1,959
Interests in associates		**—**	—
Deferred tax assets		**19,847**	12,453
		39,905	36,187
Current assets			
Inventories		**6,334**	11,737
Trade and other receivables	*8*	**87,483**	44,858
Other current assets		**24,255**	2,103
Financial assets at fair value through profit or loss		**—**	32,088
Cash and cash equivalents		**192,321**	24,155
		310,393	114,941
Current liabilities			
Trade and other payables	*9*	**37,494**	20,671
Bank loans		**30,000**	30,000
Lease liabilities		**688**	1,490
		68,182	52,161
Net current assets		**242,211**	62,780
Total assets less current liabilities		**282,116**	98,967
Non-current liabilities			
Lease liabilities		**781**	1,118
Financial instruments issued to investors		**—**	1,043,745
		781	1,044,863
NET ASSETS/(LIABILITIES)		**281,335**	(945,896)

	December 31 2020 *RMB'000*	December 31 2019 *RMB'000*
CAPITAL AND RESERVES		
Paid-in capital	**—**	11,483
Share capital	**200,000**	—
Reserves	**81,335**	(950,336)
Total equity attributable to equity shareholders of the Company	**281,335**	(938,853)
Non-controlling interests	**—**	(7,043)
TOTAL EQUITY	**281,335**	(945,896)

Notes:

1. General Information

Suzhou Basecare Medical Corporation Limited, formerly known as Jiangsu Double Helix Biological Technology Co., Ltd., was established in Suzhou, the PRC on December 14, 2010 as a limited liability company. Upon approval by the Company's board meeting held on August 11, 2020, the Company was converted from a limited liability company into a joint stock limited liability company and changed its registered name from Jiangsu Double Helix Biological Technology Co., Ltd. to Suzhou Basecare Medical Corporation Limited.

The Company is an investment holding company. The Company and its subsidiaries are principally engaged in provision of genetic testing solution for assisted reproduction and sale of genetic testing devices and instruments in the PRC.

The H shares of the Company were listed on the Stock Exchange on February 8, 2021.

2. Significant accounting policies

(a) Statement of Compliance

These financial statements have been prepared in accordance with all applicable International Financial Reporting Standards (IFRSs), which collective term includes all applicable individual International Financial Reporting Standards, International Accounting Standards (IASs) and Interpretations issued by the International Accounting Standards Board ("**IASB**") and the disclosure requirements of the Hong Kong Companies Ordinance. These financial statements also comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Stock Exchange.

The IASB has issued certain amendments to IFRSs that are first effective or available for early adoption for the current accounting period of the Group. Note 2(c) provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current and prior accounting periods reflected in these financial statements.

(b) Basis of preparation of the financial statements

The consolidated financial statements for the year ended December 31, 2020 comprise the Company and its subsidiaries and the Group's interest in associates.

The measurement basis used in the preparation of the financial statements is the historical cost basis except that the assets are stated at their fair value.

The preparation of financial statements in conformity with IFRSs requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

(c) Changes in accounting policies

The IASB has issued the following amendments to IFRSs that are first effective for the current accounting period of the Group:

- Amendments to IFRS 3, *Definition of a Business*
- Amendments to *IFRS 9, IAS 39 and IFRS 7, Interest Rate Benchmark Reform*
- Amendments to IAS 1 and IAS 8, *Definition of Material*
- Amendments to References to Conceptual Framework in IFRS Standards
- Amendment to IFRS 16, *Covid-19-Related Rent Concessions*

None of these developments have had a material effect on how the Group's results and financial position for the current or prior periods have been prepared or presented. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period except for the amendment to IFRS 16, *Covid-19-Related Rent Concessions*, which provides a practical expedient that allows lessees not to assess whether particular rent concessions occurring as a direct consequence of the COVID-19 pandemic are lease modifications and, instead, account for those rent concessions as if they were not lease modifications.

3. Revenue

The Group derives revenue from the provision of genetic testing solutions and sales of genetic testing devices and instruments. Genetic testing solutions consist of (i) sales of testing kits and (ii) provision of testing services.

(a) Disaggregation of revenue

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
Revenue from contracts with customers within the scope of IFRS 15		
Genetic testing solutions		
— Sales of testing kits	**62,596**	24,513
— Provision of testing services	**6,331**	28,801
Sales of testing devices and instruments	**12,182**	2,371
	81,109	55,685

During the year ended December 31, 2020 and 2019, the Group recognised its revenue from contract with customers at point.

The Group has applied the practical expedient in paragraph 121 of IFRS 15 to its sales contracts of products and services such that the Group does not include information about revenue that the Group will be entitled to when it satisfied the remaining performance obligations for sales of products and provision of services that had an original expected duration of one year or less.

(b) Information about major customers

Revenue from major customers contributing over 10% of the Group's revenue are set out as below:

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
Customer A	**8,673**	6,648
Customer B	**9,689**	N/A*
	18,362	6,648

* Less than 10% of the Group's revenue in the respective year.

(c) Geographic information

All of the non-current assets of the Group are physically located in the PRC. The geographical location of customers is based on the location at which the customers operate and the revenue of the Group is almost all derived from operations in the PRC during the reporting period.

(d) Segment reporting

IFRS 8, *Operating Segments*, requires identification and disclosure of operating segment information based on internal financial reports that are regularly reviewed by the Group's chief operating decision maker for the purpose of resources allocation and performance assessment. On this basis, the Group has determined that it only has one operating segment which is the provision of genetic testing solutions and sales of genetic testing devices and instruments during the reporting period.

4. Other income

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
Government grants [(i)]	**1,499**	2,428
Interest income from bank deposits	**520**	64
Net realised and unrealised gains on financial assets measured at fair value through profit or loss	**103**	875
Others	**668**	591
	2,790	3,958

(i) Government grants comprise primarily subsidies received from the government for encouragement of research and development projects and compensation on the incurred rental expenditure on the buildings rented for research and development activities.

5. Loss before taxation

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
(a) Finance costs		
Interest on bank loans	**1,376**	1,206
Interest on lease liabilities	**96**	110
	1,472	1,316
(b) Staff costs		
Salaries, wages and other benefits	**34,557**	23,071
Contributions to defined contribution retirement plan [(i)]	**221**	1,930
	34,778	25,001

(i) Employees of the Group's PRC subsidiaries are required to participate in a defined contribution retirement scheme administered and operated by the local municipal government. The Group's PRC subsidiaries contribute funds which are calculated on certain percentages of the average employee salary as agreed by the local municipal government to the scheme to fund the retirement benefits of the employees.

The Group has no other material obligation for the payment of retirement benefits associated with the scheme beyond the annual contributions described above.

(c) Other items

	2020	2019
	RMB'000	*RMB'000*
Depreciation of property, plant and equipment	**4,963**	6,088
Depreciation of right-of-use assets	**1,592**	1,932
Impairment losses/(reversal of impairment losses) on trade and other receivables	**61**	(5)
Auditors' remuneration	**361**	15
Research and development expenses [(i)]	**34,481**	19,885
Cost of inventories [(ii)]	**42,338**	17,811
Foreign exchange losses	**8,553**	5

(i) During the year ended December 31, 2020, research and development expenses include staff costs and depreciation expenses of RMB14,641,000 (2019: RMB11,215,000), which amounts are also included in the respective total amounts disclosed separately above.

(ii) During the year ended December 31, 2020, cost of inventories includes staff costs and depreciation expenses of RMB1,835,000 (2019: RMB2,539,000), which amounts are also included in the respective total amounts disclosed separately above.

6. Income tax in the consolidated statement of profit or loss and other comprehensive income

(a) Taxation in the consolidated statement of profit or loss and other comprehensive income represents:

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
Current tax — PRC Tax	**—**	—
Deferred tax	**(7,394)**	(2,290)
Total	**(7,394)**	(2,290)

(b) Reconciliation between tax expense and accounting loss at applicable tax rates:

	2020	2019
	RMB'000	*RMB'000*
Continuing operations		
Loss before taxation	**(881,518)**	(530,570)
Notional tax on loss before taxation, calculated at the rates applicable to profits in the PRC [(i)]	**(220,380)**	(132,643)
Effect of preferential tax rate [(ii)&(iv)]	**3,315**	1,051
Effect of additional deduction on research and development expenses [(iii)]	**(2,754)**	(1,514)
Tax effect of changes in the carrying amount of financial instruments issued to investors	**206,707**	130,112
Tax effect of other non-deductible expenses	**272**	839
Tax effect of non-taxable income	**(3,325)**	—
Utilisation of tax losses not recognised	**—**	(54)
Tax effect of tax losses not recognised	**8,071**	—
Utilisation of deductible temporary differences not recognised	**(63)**	—
Tax effect of deductible temporary differences not recognised	**—**	3
Others	**763**	(84)
Actual tax expense	**(7,394)**	(2,290)

(i) Effective from January 1, 2008, the PRC statutory income tax rate is 25% under the PRC Enterprise Income Tax Law. The Group's subsidiaries in the PRC are subject to PRC income tax at 25% unless otherwise specified.

(ii) According to the PRC income tax law and its relevant regulations, entities that qualified as high-technology enterprise are entitled to a preferential income tax rate of 15%. Basecare Medical Device obtained its renewed certificate of high-technology enterprise on 2 December 2020 and is subject to income tax at 15% for a three years period.

(iii) During the year, an additional 75% of qualified research and development expenses incurred is allowed to be deducted from taxable income under the PRC income tax law and its relevant regulations.

(iv) According to the PRC income tax law and its relevant regulations issued in 2019, entities that qualified as small and low profit enterprise are entitled to a preferential income tax rate of 5% (for taxable income less than RMB1,000,000) or 10% (for taxable income range from RMB1,000,000 to RMB3,000,000). Basecare Intelligent Manufacturing was qualified as small and low profit enterprise and entitled to the preferential income tax rate of 5% for the year ended December 31 2020 and 2019.

7. Loss per share

The calculation of basic loss per share for the year ended December 31, 2020 is based on the loss for the year attributable to shareholders of the Company of RMB877,052,000 (2019: RMB531,336,000) and the weighted average number of ordinary shares of 171,909,908 in issue during the year (2019: 147,694,787). The weighted average number of ordinary shares in issue before the conversion into a joint stock limited liability company was determined by assuming that the paid-in capital had been fully converted into share capital at the same conversion ratio as upon transformation into a joint stock limited liability company in August 2020.

There were no potential dilutive ordinary shares for the year ended December 31, 2020 and 2019, and therefore dilutive loss per share are the same as the basic loss per share.

8. Trade and other receivables

	2020	2019
	RMB'000	*RMB'000*
Trade receivables		
Receivables from third parties	**55,430**	37,568
Receivables from related parties	**20,793**	2,879
Less: losses allowance on trade receivables	**(412)**	(351)
Trade receivables, net	**75,811**	40,096
Amount due from related parties	**5,100**	—
Prepayments to suppliers	**3,610**	2,299
Deposits	**942**	939
Other receivables	**2,020**	1,524
Trade and other receivables, net	**87,483**	44,858

(a) Ageing analysis of trade receivables

As of the end of the reporting period, the ageing analysis of the Group's trade receivables, based on the invoice date and net of losses allowance, is as follows:

	2020	2019
	RMB'000	*RMB'000*
Within 6 months	**52,389**	30,347
6–12 months	**18,684**	8,818
12–18 months	**4,715**	902
18–24 months	**23**	—
Over 2 years	**—**	29
	75,811	40,096

Trade receivables are generally due within 60 to 240 days from the date of billing.

9. Trade and other payables

	2020	2019
	RMB'000	*RMB'000*
Trade payables [(i)]	**11,131**	9,749
Payroll payables	**3,841**	3,457
Payables for marketing expenses	**1,726**	5,328
Accrued listing expenses	**15,435**	—
Interest payables	**22**	47
Other payables and accruals	**5,339**	2,090
	37,494	20,671

(i) As of the end of the reporting period, the ageing analysis of the Group's trade payables, based on the invoice date, is as follows:

	2020	2019
	RMB'000	*RMB'000*
Within 3 months	**4,159**	2,743
3–6 months	**4,626**	4,566
6–9 months	**1,706**	2,370
9–12 months	**—**	—
Over 1 year	**640**	70
	11,131	9,749

All of the trade and other payables are expected to be settled within one year.

FINANCIAL REVIEW

Revenue

During the Reporting Period, we generated revenue from the provision of genetic testing solutions and sales of genetic testing devices and instruments.

Our revenue increased by 45.7% from RMB55.7 million for the year ended December 31, 2019 to RMB81.1 million for the year ended December 31, 2020. This increase was primarily driven by the increase in revenue from our genetic testing solutions and, to a lesser extent, by the revenue we generated from sales of testing devices and instruments.

Cost of Sales

Our cost of sales consists of (i) material costs, representing purchase costs of the distributed products and raw material cost for our self-developed products, (ii) staff costs, (iii) depreciation expenses, which primarily include depreciation of property, plant and equipment and right-of-use assets, (iv) testing service fees, which primarily include outsourcing service fees we paid to third-party medical laboratories for certain sequencing services, and (v) others, which primarily include insurance premiums for policies we purchased to insure subjects who were tested by our PGT-A kit, logistics expenses and equipment maintenance expenses.

Our cost of sales increased by 81.4% from RMB29.4 million for the year ended December 31, 2019 to RMB53.4 million for the year ended December 31, 2020, primarily due to an increase in material costs as a result of our increased purchase costs of NIPT and MGD kits, which were in line with our increased sales and distribution of NIPT and MGD kits.

Gross Profit and Gross Profit Margin

As a result of the aforementioned factors, the gross profit of the Group increased from RMB26.3 million for the year ended December 31, 2019 to RMB27.7 million for the year ended December 31, 2020. Gross profit margin is calculated as gross profit divided by revenue. The overall gross profit margin of the Group decreased from 47.1% for the year ended December 31, 2019 to 34.2% for the year ended December 31, 2020, primarily due to increased sales of NIPT and MGD kits we distributed in the latter period, which had lower gross profit margins compared to our self-developed test kits.

Other Income

Our other income decreased by 29.5% from RMB4.0 million for the year ended December 31, 2019 to RMB2.8 million for the year ended December 31, 2020, primarily due to a decrease in government grants we received.

Distribution Costs

Our distribution costs increased by 50.9% from RMB11.0 million for the year ended December 31, 2019 to RMB16.6 million for the year ended December 31, 2020, primarily due to an RMB2.6 million increase in our marketing expenses because we began to engage an Independent Third Party to provide marketing services in the year of 2020 and the amount incurred for such marketing services also increased compared to that in the year of 2019.

Administrative Expenses

Our administrative expenses increased significantly from RMB8.0 million for the year ended December 31, 2019 to RMB25.2 million for the year ended December 31, 2020, primarily due to a RMB7.4 million increase in our staff costs as a result of increased headcount and discretionary bonus we paid to our management team and the listing expenses of RMB8.4 million incurred in connection with the Listing.

Research and Development Expenses

The following table sets forth the components of our research and development expenses for the year indicated.

	For the year ended December 31,			
	2020		2019	
	RMB'000		*RMB'000*	
Staff costs	**12,730**	**15.7%**	9,062	16.3%
Clinical trial expenses	**8,032**	**9.9%**	3,047	5.5%
Technical service fees	**4,877**	**6.0%**	2,469	4.4%
Consumables expenses	**6,237**	**7.7%**	2,254	4.0%
Depreciation expenses	**1,911**	**2.4%**	2,153	3.9%
Others	**694**	**0.8%**	900	1.6%
Total	**34,481**	**42.5%**	19,885	35.7%

Our research and development expenses increased by 73.4% from RMB19.9 million for the year ended December 31, 2019 to RMB34.5 million for the year ended December 31, 2020, primarily due to (i) a RMB5.0 million increase in service fees we paid to technical service suppliers mainly for the preclinical verification fees for our PGT-M kits, (ii) a RMB3.7 million increase in our staff costs as a result of increased headcount for our research and development personnel, and (iii) a RMB4.0 million increase in consumables expenses for development and registration testing of our PGT-SR, WES, PGT-M and CNV kits.

Finance Costs

Our financial costs consist of (i) interest on interest-bearing bank loans, and (ii) interest on lease liabilities. We recorded finance costs of RMB1.3 million and RMB1.5 million for the years ended December 31, 2019 and 2020, respectively.

Carrying Amount of Financial Instruments Issued to Investors

We issued shares to a group of Pre-IPO Investors in relation to our Series A, Series B and Series C Investments, which were recognized as financial liabilities because these financial instruments did not meet the definition of equity for the Company. The aggregate carrying amount of these financial instruments as of December 31, 2019 and 2020 was RMB1,043.7 million and nil, respectively. Changes in the carrying amount of these financial instruments amounted to RMB520.4 million and RMB826.8 million for the years ended December 31, 2019 and 2020, respectively. On July 23, 2020, we entered into supplementary investment agreements with the Pre-IPO Investors, pursuant to which the Pre-IPO Investors waived certain priority rights. These agreements enabled these financial instruments to be classified into our equity on July 23, 2020, after which we no longer recognized these financial instruments as financial liabilities or any changes in the carrying amount of such financial liabilities in our statements of profit or loss.

Income Tax

We recorded income tax credit of RMB2.3 million and RMB7.4 million for the years ended December 31, 2019 and 2020, respectively.

Discontinued Operations

In the first half of 2020, we disposed of Suzhou Medical Laboratory, Shandong Medical Laboratory and Benxi Medical Laboratory, together with their operations, respectively, to Suzhou Double Helix. We decided to discontinue these operations as part of our efforts to focus on our positioning as a R&D-focused provider of genetic testing solutions, rather than a provider of testing services. In June 2020, we disposed of Suzhou Laman Medical Equipment Co., Ltd. (蘇州拉曼醫療器械有限公司), which did not carry on any business since its incorporation, to an Independent Third Party. In July 2020, we disposed of Fanghua Gene to Nanjing Fanghua, an Independent Third Party. We recorded losses from discontinued operations of RMB5.7 million and RMB3.8 million for the years ended December 31, 2019 and 2020, respectively.

Inventories

Our inventories primarily consist of raw materials, finished goods and devices and instruments. We generally purchase raw materials for our in-house products based on the orders received. We maintain a finished goods inventory for our PGT-A kits and the NIPT kits we distribute. We also maintain a device and instrument inventory for DA8600s we distribute.

Our inventories decrease from RMB11.7 million as of December 31, 2019 to RMB6.3 million as of December 31, 2020, primarily due to a decrease of finished goods driven by increased sales.

Trade and Other Receivables

Our trade and other receivables increased from RMB44.9 million as of December 31, 2019 to RMB87.5 million as of December, 2020, primarily due to increased trade receivable balances due from disposed medical laboratories after the disposal. The increased trade receivable balances due from disposed medical laboratories were primarily due to (i) disposals of these medical laboratories, and (ii) our increased sales of genetic test kits to these medical laboratories.

Foreign Exchange Risk

Our financial statements are expressed in RMB, but certain of our cash and cash equivalents are denominated in foreign currencies, and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Financial Assets at Fair Value through Profit or Loss ("FVTPL")

As of December 31, 2019 and 2020, we had financial assets at fair value through profit or loss of RMB32.1 million and nil, respectively. Our financial assets at fair value through profit or loss represent wealth management products we purchased from commercial banks in the PRC.

Trade and Other Payables

Our trade payables increased from RMB9.7 million as of December 31, 2019 to RMB11.1 million as of December 31, 2020, primarily due to our increased purchases of MGD kits.

Our other payables increased from RMB10.9 million as of December 31, 2019 to RMB26.4 million as of December 31, 2020, primarily attributable to an increase in accrued listing expenses.

Financial Resources, Liquidity and Capital Structure

Our net current assets increased significantly from RMB62.8 million as of December 31, 2019 to RMB242.2 million as of December 31, 2020, primarily due to (i) an increase in cash and cash equivalents because we received proceeds from Series D Pre-IPO Investors in July 2020, and (ii) an increase in trade and other receivables as a result of our business growth, partially offset by a decrease in financial assets at fair value through profit or loss as a result of our disposal of wealth management products.

As of December 31, 2020, we had unsecured bank loans of RMB30.0 million with an interest rate of 4.35% per annum. The unsecured bank loans of RMB30.0 million were guaranteed by a subsidiary of our Group.

Due to the Global Offering, we have received net proceeds of approximately HK$1,898.7 million (after deduction of underwriting fees, commissions and relevant expenses). The Company intends to apply such net proceeds in accordance with the purposes as set out in the section headed "Future Plans and Use of Proceeds" in the prospectus of the Company dated January 27, 2021.

Significant Investments, Material Acquisitions and Disposals

In anticipation of the Listing, to streamline our business structure and taking into consideration of our future business strategy and relevant PRC laws and regulations regarding foreign investment in certain businesses under the Special Administrative Measures (Negative List) for the Access of Foreign Investment (外商投資准入特別管理措施(負面清單)), we disposed 100% of the equity interests in Suzhou Medical Laboratory, 51% equity interests in Shandong Medical Laboratory, 51% equity interests in Benxi Medical Laboratory, 20% equity interests in Suzhou Chaoyun, 70% equity interests in Suzhou Laman Medical Equipment Co., Ltd., 51% equity interests in Suzhou Fanghua Gene Technology Co., Ltd. and 20% equity interests in Suzhou Fanghua Biotechnology Co., Ltd. during the Reporting Period.

Particulars of the aforementioned acquisition are set out in the section headed "History and Corporate Structure" of the Prospectus.

Save as disclosed above, during the Reporting Period, we did not make any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures.

Future Plans for Material Investments or Capital Assets

As disclosed in the announcement of the Company dated March 4, 2021, the Company acquired the land use right of a piece of land of a total site area of 21,626.14 sq.m. to the east of Xingtang Street and north of Jiangyun Road, Suzhou Industrial Park, Jiangsu, PRC at a total consideration of RMB7,960,000 to be used for the construction of the headquarters of the Company. Save for the above, the Group had no material capital expenditure plan as of the date of this annual results announcement.

Contingent Liabilities

As of December 31, 2020, we did not have any contingent liabilities.

Capital Commitments

As of December 31, 2020, we did not have any material capital commitments.

Charge on Assets

There were no charges on the Group's assets as of December 31, 2020.

Gearing Ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of December 31, 2020, the Company was in a net cash position and thus, gearing ratio is not applicable.

Employees and Remuneration

As of December 31, 2020, the Group had 192 employees. The total staff cost incurred by the Group for the year ended December 31, 2020 was RMB34.8 million, as compared to RMB25.0 million for the year ended December 31, 2019. The remuneration package of our employees includes salary and bonus, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations.

OTHER INFORMATION

Corporate Governance Practices

As the Shares of the Company were not listed on the Stock Exchange as of December 31, 2020, the CG Code was not applicable to the Company during the Reporting Period, but has become applicable to the Company since the Listing Date.

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and enhance its corporate value. The Company has adopted the CG Code as its own code of corporate governance since the Listing Date. The Company has complied with all applicable code provisions as set out in the CG Code during the period from the Listing Date and up to the date of this annual results announcement, except for a deviation from the code provision A.2.1 of the CG Code, the roles of chairman and general manager of the Company are not separate and are both performed by Dr. Liang.

The Board believes that vesting the roles of both chairman of the Board and general manager of the Company in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the general manager of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

Directors' and Supervisors' Securities Transactions

As the Shares of the Company were not listed on the Stock Exchange as of December 31, 2020, related rules under the Model Code that Directors shall observe did not apply to the Company during the Reporting Period.

The Company has adopted the Model Code as its own code of conduct regarding Directors' and Supervisors' securities transactions since the Listing Date. Having made specific enquiry of all Directors and Supervisors, each of the Directors and Supervisors has confirmed that he/she has complied with the Model Code during the period from the Listing Date and up to the date of this annual results announcement.

No incident of non-compliance of the Model Code was noted by the Company during the period from the Listing Date and up to the date of this annual results announcement.

Company's Compliance with relevant Laws and Regulations

During the Reporting Period and up to the date of this annual results announcement, the Group had complied with the laws, regulations and regulatory requirements of the places where the Group operates in all material respects, including the requirements under the Companies Ordinance, the Listing Rules, the SFO and the CG Code for, among other things, the disclosure of information and corporate governance. During the Reporting Period and up to the date of this annual results announcement, none of the Group and the Directors, Supervisors and senior management of the Company were subject to any investigation initiated or administrative penalties imposed by the CSRC, banned from entering the market, identified as inappropriate candidates, publicly condemned by stock exchanges, subject to mandatory measures, transferred to judicial organs or held criminally responsible, and none were involved in any other litigation, arbitration or administrative proceedings which would have a material adverse impact on our business, financial condition or results of operations.

Use of Proceeds from the Global Offering

The net proceeds received by the Company from its initial global offering (including the partial exercise of the over-allotment option) amounted to HK$1,898.7 million (equivalent to RMB1,584.1 million) (after deducting the underwriting commissions and relevant expenses). As of December 31, 2020, the Company did not utilize any of the proceeds from the Global Offering.

The Company intends to use the net proceeds in the same manner and proportion as set out in the Prospectus under the section headed "Future Plans and Use of Proceeds". For details of the breakdown of the use of proceeds, please refer to the 2020 annual report of the Company to be published in due course.

Final Dividends

The Directors do not recommend the payment of a final dividend for the Reporting Period.

Annual General Meeting (the "AGM")

The AGM of the Company will be held on June 8, 2021. The notice of the AGM will be sent to the Shareholders at least 20 clear business days before the AGM.

Closure of Register of Members

For the purpose of determining the Shareholders who are entitled to attend and vote at the AGM, the register of members of the Company will be closed from May 8, 2021 to June 8, 2021 both days inclusive. In order to qualify for attending and voting at the AGM, all transfer documents should be lodged for registration with Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on May 7, 2021.

Purchase, Sale or Redemption of the Listed Securities of the Company

Save for the Company's initial public offering (including the partial exercise of the over-allotment option), there is no other issue of Shares by the Company, and neither the Company nor any of its subsidiaries had purchased, sold or redeemed any other listed securities of the Company during the period from the Listing Date and up to the date of this annual results announcement.

Scope of Work of the Auditor

The financial figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2020 as set out herein have been compared by the Group's auditor, KPMG, Certified Public Accountants, to the amounts set out in the Group's audited consolidated financial statements for the year and the amounts were found to be in agreement. The work performed by KPMG in this respect did not constitute an audit, review or other assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the auditor.

Audit Committee

The Audit Committee consists of two independent non-executive Directors and one non-executive Director, namely Mr. YU Kwok Kuen Harry, Dr. KANG Xixiong and Mr. WANG Weipeng. Mr. YU Kwok Kuen Harry, being the chairman of the Audit Committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Company and overseeing the audit process.

The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Company and consolidated financial statements for the year ended December 31, 2020.

Publication of Annual Results and Annual Report

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.basecare.cn). The annual report for the year ended December 31, 2020 containing all the information in accordance with the requirements under the Listing Rules will be despatched to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Company's principal place of business in Hong Kong has been changed to 40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road East, Wanchai, Hong Kong with effect from March 30, 2021.

APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By Order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, March 30, 2021

As of the date of this announcement, the Board comprises Mr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Mr. KANG Xixiong, Mr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive Directors.

"Articles of Association"	articles of association of our Company adopted on August 31, 2020, as amended from time to time
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Audit Committee"	the audit committee of the Board
"Benxi Medical Laboratory"	Benxi Shengjing Medical Laboratory Co., Ltd. (本溪盛京醫學檢驗所有限公司), a company established in the PRC with limited liability on February 4, 2017 and a connected person of our Company
"Board" or "Board of Directors"	the board of directors of the Company
"CG Code"	the CG Code as set out in Appendix 14 to the Listing Rules
"China" or "the PRC"	the People's Republic of China excluding, for the purpose of this annual results announcement, Hong Kong, Macau Special Administrative Region and Taiwan
"Company", "our Company" or "the Company"	Suzhou Basecare Medical Corporation Limited (蘇州貝康醫療股份有限公司), previously known as Jiangsu Double Helix Biology Science and Technology Co., Ltd. (江蘇雙螺旋生物科技有限公司), Saiye Health Research Center (Taicang) Co., Ltd. (賽業健康研究中心(太倉)有限公司) or Saiye (Suzhou) Biological Information Technology Co., Ltd. (賽業(蘇州)生物信息技術有限公司), a company incorporated in the PRC with limited liability on December 14, 2010 and converted into a joint stock company with limited liability on August 27, 2020
"Controlling Shareholder(s)"	has the meaning ascribed thereto under the Listing Rules and unless the context requires otherwise, refers to Dr. Liang and/or Basecare Investment
"Core Product"	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for purposes of this annual results announcement, for the purposes of this annual results announcement, our Core Product refers to our PGT-A kit

"CSRC"	China Securities Regulatory Commission
"Director(s)"	the director(s) of the Company
"Domestic Shares"	ordinary shares in the share capital of our Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi by domestic investors
"Dr. Liang"	Dr. LIANG Bo (梁波), our founder, executive Director, chairman of the Board, general manager and Controlling Shareholder
"Frost & Sullivan"	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., a global market research and consulting company, which is an Independent Third Party
"Global Offering"	the offer of H Shares for subscription as described in the Prospectus
"Group", "we" or "us"	the Company and its subsidiaries
"H Shares"	overseas listed shares in the share capital of our Company with a nominal value of RMB1.00 each, which are subscribed for and traded in HK dollars
"H Share Registrar"	Computershare Hong Kong Investor Services Limited
"Hillhouse HK"	HH SPR-XIV HK Holdings Limited, a limited company incorporated in Hong Kong on July 12, 2018 and a Pre-IPO Investor
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"IFRS"	International Financial Reporting Standards
"Independent Third Party(ies)"	an individual or a company which, to the best of our Directors' knowledge, information, and belief, having made all reasonable enquiries, is not a connected person of our Company within the meaning of the Listing Rules

"Listing" or "IPO"	the listing of the H Shares on the Main Board of the Stock Exchange on the Listing Date
"Listing Date"	February 8, 2021, being the date on which the H Shares were listed on the Main Board
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Main Board"	the Main Board of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules
"NMPA"	the National Medical Products Administration of China (國家藥品監督管理局) or, where the context so requires, its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局), or CFDA
"Nomination Committee"	the nomination committee of the Board
"Pre-IPO Investor(s)"	the investor(s) of the pre-IPO investments of the Company
"Prospectus"	the prospectus issued by the Company dated January 27, 2021
"Renminbi" or "RMB"	Renminbi Yuan, the lawful currency of China
"Reporting Period"	the year from January 1, 2020 to December 31, 2020
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
"Shandong Medical Laboratory"	Shandong Beikang Medical Laboratory Co., Ltd. (山東貝康醫學檢驗所有限公司), a company incorporated in the PRC with limited liability on August 3, 2016 and a connected person of our Company
"Shareholder(s)"	holder(s) of the Shares

"Share(s)"	shares in the share capital of our Company, with a nominal value of RMB1.00 each
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Supervisor(s)"	the supervisor(s) of the Company
"Suzhou Chaoyun"	Suzhou Chaoyun Life Intelligence Industry Research Institute Co., Ltd. (蘇州超雲生命智能產業研究院有限公司), a company incorporated in the PRC with limited liability on February 8, 2018 and an Independent Third Party
"Suzhou Double Helix"	Suzhou Double Helix Medical Laboratory Co., Ltd. (蘇州雙螺旋醫學檢驗所有限公司), a company incorporated in the PRC with limited liability on April 1, 2020 and a connected person of our Company
"Suzhou Medical Laboratory"	Suzhou Beikang Medical Laboratory Co., Ltd. (蘇州貝康醫學檢驗實驗室有限公司), a company incorporated in the PRC with limited liability on August 9, 2018 and a connected person of our Company